Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen.

Oncotarget - 12 Jul 2016

Jansen Maurice Phm, Martens John Wm, Helmijr Jean Ca, Beaufort Corine M, van Marion Ronald, Krol Niels Mg, Monkhorst Kim, Trapman-Jansen Anita Mac, Meijer-van Gelder Marion E, Weerts Marjolein Ja, Ramirez-Ardila Diana E, Dubbink Hendrikus Jan, Foekens John A, Sleijfer Stefan, Berns Els Mjj

Abstract excerpt

The aim was to identify mutations in serum cell-free DNA (cfDNA) associated with disease progression on tamoxifen treatment in metastatic breast cancer (MBC). Sera available at start of therapy, during therapy and at disease progression were selected from 10 estrogen receptor (ER)-positive breast cancer patients. DNA from primary tumor and normal tissue and cfDNA from minute amounts of sera were analyzed by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A Kinase Anchor Proteins
Share to Antineoplastic Agents, Hormonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast

Share to Cell-Free Nucleic Acids

Share to Class I Phosphatidylinositol 3-Kinases

Share to CREB-Binding Protein

Share to Smad4 Protein

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 27270325
DOI: 10.18632/oncotarget.9727
PMCID: PMC5190033

Genes

AKAP9
CREBBP
SMAD4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen.PMID 27270325Read ↗

Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patientsSemantic proximity Read ↗

Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.Semantic proximity Read ↗

Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.Semantic proximity Read ↗

The use of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) to guide treatment selection in metastatic breast cancer.Semantic proximity Read ↗

High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.Semantic proximity Read ↗

Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer.Semantic proximity Read ↗

Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.Semantic proximity Read ↗

High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer.Semantic proximity Read ↗

Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer.Semantic proximity Read ↗

Targeted Sequencing of Plasma-Derived vs. Urinary cfDNA from Patients with Triple-Negative Breast CancerSemantic proximity Read ↗

Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease.Semantic proximity Read ↗

Use of cell free DNA in breast oncology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.